Lactoferrin
Doctor's Data
Sample type: Stool
Requires fasting: No
At home test
Details
Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two chronic conditions associated with diarrhea and abdominal pain, and these symptoms are among the most common reasons that patients seek medical advice.
- Lactoferrin, Stool [Mass/Volume]
Estimated days for results: Results should arrive 5 to 7 days after the lab receives samples.
Fecal lactoferrin is a biomarker of serious gastrointestinal inflammation. Fecal lactoferrin is elevated in association with Inflammatory Bowel Disease (IBD) such as Ulcerative Colitis (UC) or Crohn's Disease (CD), but NOT Irritable Bowel Syndrome (IBS). Therefore, assessment of fecal lactoferrin levels enables distinction between IBD and non-inflammatory IBS. Such distinction is critical because, although both IBD and IBS may share some common symptoms such as diarrhea, abdominal cramping and weight loss, the diseases are treated quite differently. IBD may become life threatening, requires life-long treatment and possibly surgery. In contrast, IBS is often effectively treated with dietary restrictions, stress reduction and medication.
Gastrointestinal inflammation associated with IBD is associated with increased infiltration of activated neutrophils into the mucosa and increased release of lactoferrin into the gut. Patients with inflammation of the GI tract, such as IBD (but not IBS), exhibit elevated lactoferrin concentrations in the feces.
Clinical studies have shown that fecal lactoferrin levels of healthy persons are similar to IBS patients, but markedly increased in patients with active IBD. Patients with IBD oscillate between active and inactive disease states, and fecal lactoferrin levels increase 2-3 weeks prior to onset of clinical symptoms. During remission and effective treatment, fecal lactoferrin decreases significantly. Therefore disease activity, and efficacy of treatment can be monitored by following fecal lactoferrin levels.
Gastrointestinal inflammation associated with IBD is associated with increased infiltration of activated neutrophils into the mucosa and increased release of lactoferrin into the gut. Patients with inflammation of the GI tract, such as IBD (but not IBS), exhibit elevated lactoferrin concentrations in the feces.
Clinical studies have shown that fecal lactoferrin levels of healthy persons are similar to IBS patients, but markedly increased in patients with active IBD. Patients with IBD oscillate between active and inactive disease states, and fecal lactoferrin levels increase 2-3 weeks prior to onset of clinical symptoms. During remission and effective treatment, fecal lactoferrin decreases significantly. Therefore disease activity, and efficacy of treatment can be monitored by following fecal lactoferrin levels.
5–7 business days
- Add-on: Beta-glucuronidase
- Add-on: Calprotectin
- Add-on: Elastase
- Add-on: H. Pylori Antigen
- Add-on: Lysozyme
- Add-on: Secretory IgA
- Add-on: Zonulin Family Protein
Please read all of the directions, and familiarize yourself with the collection
procedures.
If you are taking antifungal or antibiotic medications, please
finish the course of medication, and then wait three days before starting this
collection.
Please refrain from taking digestive enzymes, antacids, and aspirin
for two days prior to and during the specimen collection, unless otherwise
instructed by your physician.
Never discontinue prescription medications without first consulting your physician.
procedures.
If you are taking antifungal or antibiotic medications, please
finish the course of medication, and then wait three days before starting this
collection.
Please refrain from taking digestive enzymes, antacids, and aspirin
for two days prior to and during the specimen collection, unless otherwise
instructed by your physician.
Never discontinue prescription medications without first consulting your physician.
State restrictions:
Patient can't order this test if they are located in Hawaii, Puerto Rico, New Jersey, New York, or Rhode Island
